NASDAQ:ERYPErytech Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Erytech Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.50 +0.87 (+10.08 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$8.82Now: $9.50▼$9.7950-Day Range$5.15MA: $7.67▼$10.9752-Week Range$3.50Now: $9.50▼$12.00Volume2,110 shsAverage Volume3,869 shsMarket Capitalization$170.43 millionP/E RatioN/ADividend YieldN/ABeta2.54 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingErytech Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Erytech Pharma has a potential upside of 36.8% from its current price of $9.50.Amount of Analyst CoverageErytech Pharma has received no research coverage in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesErytech Pharma has received 152 “outperform” votes. (Add your “outperform” vote.)Underperform VotesErytech Pharma has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentErytech Pharma has received 58.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote “Outperform” if you believe ERYP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldErytech Pharma does not currently pay a dividend.Dividend GrowthErytech Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erytech Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 7.44% of the stock of Erytech Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Erytech Pharma are expected to grow in the coming year, from ($3.18) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erytech Pharma is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erytech Pharma is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErytech Pharma has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP Previous Symbol CUSIPN/A CIKN/A Webwww.erytech.com Phone33-4-78-74-44-38Debt Debt-to-Equity Ratio0.15 Current Ratio4.10 Quick Ratio4.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book1.78Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees172 Outstanding Shares17,940,000Market Cap$170.43 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:ERYP Rates by TradingView Receive ERYP News and Ratings via Email Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions How has Erytech Pharma's stock been impacted by COVID-19 (Coronavirus)? Erytech Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ERYP stock has increased by 81.3% and is now trading at $9.50. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Erytech Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Erytech Pharma. How were Erytech Pharma's earnings last quarter? Erytech Pharma SA (NASDAQ:ERYP) issued its quarterly earnings results on Wednesday, March, 18th. The company reported ($1.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.35. View Erytech Pharma's earnings history. What price target have analysts set for ERYP? 2 analysts have issued 12 month target prices for Erytech Pharma's shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Erytech Pharma's share price to reach $13.00 in the next year. This suggests a possible upside of 36.8% from the stock's current price. View analysts' price targets for Erytech Pharma. Has Erytech Pharma been receiving favorable news coverage? News coverage about ERYP stock has trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Erytech Pharma earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutErytech Pharma. Are investors shorting Erytech Pharma? Erytech Pharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,600 shares, an increase of 100.0% from the April 30th total of 800 shares. Based on an average daily volume of 3,700 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the company's stock are sold short. View Erytech Pharma's Current Options Chain. Who are some of Erytech Pharma's key competitors? Some companies that are related to Erytech Pharma include Prevail Therapeutics (PRVL), MeiraGTx (MGTX), Scholar Rock (SRRK), Harpoon Therapeutics (HARP), DBV TECHNOLOGIE/S (DBVT), Rubius Therapeutics (RUBY), Autolus Therapeutics (AUTL), Innate Pharma (IPHYF), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Verona Pharma (TARA), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG) and CASI Pharmaceuticals (CASI). View all competitors. What other stocks do shareholders of Erytech Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Erytech Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), MEI Pharma (MEIP), Coherus Biosciences (CHRS) and Cellectis (CLLS). Who are Erytech Pharma's key executives? Erytech Pharma's management team includes the following people: Mr. Gil Beyen, Chairman & CEO (Age 57)Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)Mr. Eric Soyer, CFO & COO (Age 53)Dr. Alexander Scheer, Chief Scientific Officer (Age 57)Naomi Eichenbaum, Director Investor Relations When did Erytech Pharma IPO? (ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager. What is Erytech Pharma's stock symbol? Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP." How do I buy shares of Erytech Pharma? Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Erytech Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $9.50. How big of a company is Erytech Pharma? Erytech Pharma has a market capitalization of $170.43 million. The company earns $-70,180,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Erytech Pharma employs 172 workers across the globe. What is Erytech Pharma's official website? The official website for Erytech Pharma is www.erytech.com. How can I contact Erytech Pharma? Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
